Use of combinational broad-spectrum antiviral cocktail for treating current and emerging coronavirus infections


Naser Milad Biparva

Volume 4
Fall 2019 / Winter 2020

Coronaviruses pose a serious threat to the human population due to the high mortality rate of some strains such as SARS-CoV and MERS-CoV, and also the circulation of other zoonotic strains that may one day infect the human population. Despite the inevitable threat posed by coronaviruses, currently there are no vaccines, or treatment options available and thus, developing a broad-spectrum therapeutic option is crucial. In this article I will propose a novel solution to this problem by exploring the use of broad-spectrum antivirals such as Remdesivir and AM580 in the form of combinational therapy in order to treat individuals with coronavirus infections. By understanding the mechanism of action of Remdesivir and AM580, we can enhance future drug designs and also apply their principles to other diseases. The feasibility of the use of Remdesivir and AM580 in combinational therapy with respect to coronavirus infections is currently not clear, however, both Remdesivir and AM580 have shown to have a high selectivity index (SI), suggesting that they are safe to use. Additionally, other viral diseases may also benefit from the use of this combinational drug regimen due to the broad-spectrum nature of the drugs. By exploring the use of this drug regimen in dealing with coronavirus infections, not only do I propose an economical solution to a deadly problem, but it also paves the way for the use of similar implementations for other viral diseases.